AN2 Therapeutics reported second quarter 2026 financial results on August 11, 2026. The company incurred a net loss of $8.2 million, compared to $6.5 million in the prior year period. Research and development expenses increased to $6.0 million from $3.2 million due to higher clinical trial and CMC costs, while general and administrative expenses decreased to $2.9 million from $4.0 million. The company held cash, cash equivalents, and investments of $79.9 million at June 30, 2026, projecting this runway will sustain operations into 2029. Clinically, AN2 is expanding Phase 2 study start-up activities for oral epetraborole in polycythemia vera, with enrollment anticipated to commence in the fourth quarter of 2026. Enrollment continues in an investigator-initiated Phase 2 trial for M. abscessus lung disease, and positive preclinical data supports a planned Phase 2 initiation for AN2-502998 in chronic Chagas disease by year-end. AN2 Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform.

AN2 Therapeutics announced positive results from two studies evaluating its oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease. A 28-day nonhuman primate study showed that 100% of treated animals achieved parasite elimination that was maintained through four months. Additionally, a Phase 1 first-in-human study demonstrated that the compound was well tolerated and achieved plasma exposures at or above nonhuman primate efficacy thresholds.